|

Selumetinib Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: AZD6244, Koselugo

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 1

Top Sponsors

  • University of Chicago1
  • University of Alabama at Birmingham1
  • Gustave Roussy, Cancer Campus, Grand Paris1

Indications

  • Cancer3
  • Myelofibroses1
  • Chronic Myeloid Leukemia1
  • Plexiform Neurofibroma1
  • Neurofibromatosis 11

Other1 trial

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2

Birmingham, Alabama1 trial

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Childrens of Alabama

Phase 2

Chicago, Illinois1 trial

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

The University of Chicago

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.